Medical Equipment Stock Performance Review -- Xtant Medical, Second Sight Medical Products, Lantheus, and Masimo

Wednesday, July 5, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 5, 2017 /PRNewswire/ --

If you want a Stock Review on XTNT, EYES, LNTH or MASI then come over to

and sign up for your free customized report today. Four Medical Appliances and Equipment stocks have been lined up by this morning, and they are Xtant Medical Holdings Inc. (NYSE MKT: XTNT), Second Sight Medical Products Inc. (NASDAQ:
EYES), Lantheus Holdings Inc. (NASDAQ: LNTH), and Masimo Corp. (NASDAQ: MASI). As per a report on First Research, global revenue for makers of medical equipment and supplies is about $350 billion. Major markets include the US, Japan, Germany, France, Italy, the UK, and China. These free stocks reports are currently available on Simply sign up for your complimentary member access at:

Xtant Medical 

Belgrade, Montana headquartered Xtant Medical Holdings Inc.'s shares dropped 6.07%, finishing Monday's session at $0.62. A total volume of 95,580 shares was traded. Over the last month and since the start of this year, the stock has advanced 3.33% and 12.73%, respectively. The Company's shares are trading above their 50-day moving average by 12.32%. Additionally, shares of Xtant Medical, which develops, manufactures, and markets regenerative medicine products and devices in the US and internationally, have an RSI of 50.54. Your complete research report on XTNT can be retrieved for free at:

Second Sight Medical Products 

On Monday, shares in Sylmar, California headquartered Second Sight Medical Products Inc. ended the session 0.79% higher at $1.27. The stock recorded a trading volume of 1.80 million shares, which was above its three months average volume of 491,080 shares. The Company's shares have gained 11.40% in the last month and 6.72% in the previous three months. The stock is trading above its 50-day moving average by 7.99%. Moreover, shares of Second Sight Medical Products, which develops, manufactures, and markets prosthetic devices to restore functional vision to blind individuals in the US, Italy, Germany, France, and Canada, have an RSI of 59.18. A free report on EYES is just a click away at:


North Billerica, Massachusetts headquartered Lantheus Holdings Inc.'s stock declined 0.57%, to close the day at $17.55 with a total trading volume of 590,740 shares. The Company's shares have advanced 4.78% in the last one month, 42.11% over the previous three months, and 104.07% since the start of this year. The stock is trading 13.51% and 56.24% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Lantheus, which develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide, have an RSI of 65.14.

On June 14th, 2017, Lantheus announced an agreement to sell 3,000,000 shares of its common stock to be offered by certain of its existing stockholders (the "Selling Stockholders"), pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on Form S-3. The Company will not receive any proceeds from the sale of shares by the Selling Stockholders. Credit Suisse Securities and Cantor Fitzgerald & Co. will act as underwriters for the offering. Sign up for your complimentary research report on LNTH at:


Shares in Irvine, California headquartered Masimo Corp. recorded a trading volume of 240,637 shares. The stock ended at $90.38, slightly down 0.88% from the last trading session. The Company's shares have gained 34.09% on an YTD basis. The stock is trading above its 200-day moving average by 16.82%. Furthermore, shares of Masimo, which develops, manufactures, and markets noninvasive monitoring technologies worldwide, have an RSI of 46.92.

On June 05th, 2017, Masimo announced, in conjunction with its CE marking, the limited market release of the Spot-Check Rad-67™ Handheld Pulse CO-Oximeter®. Rad-67 offers Measure-through Motion and Low Perfusion™ SET® pulse oximetry and upgradeable rainbow® noninvasive monitoring technology in a compact, portable, spot-check device. With the universal reusable rainbow® DCI®-mini sensor, Rad-67 features Next Generation SpHb® (noninvasive total hemoglobin) technology. Register for free on and download the latest research report on MASI at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store